Analysts think RGNX stock price could increase by 424%
Dec 26, 2024, 12:25 PM
6.49%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
13 analysts think RGNX stock price will increase by 423.78%. The current median analyst target is $38.76 compared to a current stock price of $7.40. The lowest analysts target is $22.22 and the highest analyst target is $54.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
